Merck KGaA Licenses CRISPR Gene-Editing Technology to Evotec
By Kim Richters
Germany's Merck KGaA (MRK.XE) said Tuesday that it signed a
licensing agreement to grant Evotec SE (EVT.XE) access to its
CRISPR genome-editing technology.
The German biotechnology company will use Merck's gene-editing
technology to research, test and develop new drugs, the company
The science and technology company didn't comment on financial
terms of the deal.
Write to Kim Richters at email@example.com
(END) Dow Jones Newswires
November 12, 2019 08:38 ET (13:38 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.